Perry C. Siatis - 27 Feb 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, GC AND SECRETARY
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis
Issuer symbol
ABBV
Transactions as of
27 Feb 2026
Net transactions value
-$7,821,937
Form type
4
Filing time
03 Mar 2026, 18:10:12 UTC
Previous filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Siatis Perry C EVP, GC AND SECRETARY 1 N. WAUKEGAN ROAD, NORTH CHICAGO /s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis 03 Mar 2026 0001951400

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Tax liability $3,446,388 -14,850 -39% $232.08 23,287 27 Feb 2026 Direct
transaction ABBV Common Stock, $0.01 par value Sale $1,348,987 -5,777 -25% $233.51 17,510 02 Mar 2026 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale $2,414,886 -10,291 -59% $234.66 7,219 02 Mar 2026 Direct F2
transaction ABBV Common Stock, $0.01 par value Sale $611,676 -2,600 -36% $235.26 4,619 02 Mar 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.